Laurus Labs informs about outcome of board meeting

29 Oct 2021 Evaluate

Laurus Labs has informed that the Board of Directors of the Company in their meeting held on October 28, 2021 have resolved as follows: Approved the unaudited Standalone and Consolidated Financial Results of the Company for the Quarter and Half year ended September 30, 2021, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which are enclosed along with the Limited Review Reports issued by Deloitte Haskins & Sells LLP, the Statutory Auditors of the Company. The financial results are also available on the website of the Company at www.lauruslabs.com and also on the websites of BSE and National Stock Exchange of India: www.bseindia.com and www.nseindia.com respectively and Approved for the payment of interim dividend of Rs 0.80 (40%) per equity share of Rs 2 each, for the Financial Year 2021-22. Further, pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, the Company has fixed ‘November 18, 2021’ as ‘Record Date’ for determining the eligibility of the Shareholders. The Dividend amount will be paid on or after November 25, 2021.

The above information is a part of company’s filings submitted to BSE.

Laurus Labs Share Price

1001.00 -3.30 (-0.33%)
16-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1782.80
Dr. Reddys Lab 1279.00
Cipla 1500.00
Zydus Lifesciences 913.90
Lupin 2089.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×